Dr. Weinshilboum’s research has focussed on pharmacogenetics and pharmacogenomics, and he has authored over 375 scientific manuscripts which address these topics. A major area of investigation initially was the pharmacogenetics of drug metabolism, with a focus on methylation and sulfation but, in recent years, his research has increasingly applied genome-wide pharmacogenomic techniques, especially to study the therapy of breast cancer-rather than candidate gene or candidate pathway-based approaches. Dr. Weinshilboum has been the recipient of many awards and honors including an Established Investigatorship of the American Heart Association, a Burroughs Wellcome Scholar Award in Clinical Pharmacology Award, the Oscar B. Hunter Award of the American Society for Clinical Pharmacology and Therapeutics, the Harry Gold Award of the American Society for Pharmacology and Experimental Therapeutics, the Catecholamine Club Julius Axelrod medal, the U.S. Food and Drug Administration William B. Abrams Lectureship Award, the Edvard Poulsson Award from the Norwegian Pharmacology Society and Distinguished Medical Alumnus Award from Kansas University Medical Center. He has served on the Advisory Councils for two US NIH Institutes, the National Institute of General Medical Sciences (NIGMS) and the National Human Genome Research Institute (NHGRI).